Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.

Jonathan Trent, MD, PhD, Professor and Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami, Florida discusses the evolution of the current treatment landscape for tenosynovial giant cell tumors.

Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors by HMP Global

Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer by HMP Global

Amer Zeidan, MBBS, MHS, Yale University, discusses diagnosis and treatment of Myelodysplastic Syndrome(MDS)at 2019 ASH Meeting on Hematologic Malignancies

Newer Treatment Options for Patients With Hodgkin Lymphoma by HMP Global

Treating Newly Diagnosed Patients With MCL by HMP Global

Matthew Seymour, MD, discusses the FOxTROT trial that supports preoperative chemotherapy as a treatment with multiple, clear benefits for patients with colon cancer.

Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma by HMP Global